Faron Pharmaceuticals Limited (AIM:FARN) will hold a capital markets day on October 22 to update investors, analysts, and media on its latest developments. The event will feature presentations from Faron’s CEO, Dr. Juho Jalkanen, and other key speakers, including Dr. Mika Kontro, who will present new data from the BEXMAB clinical trial. The agenda will cover Faron’s strategy, its focus on immunotherapies, and market insights into treating cancers like myelodysplastic syndromes (MDS) and solid tumours. The event will conclude with a Q&A session.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com